“…Finally, it should be emphasized that almost 70% of the AVNA and pace analyzed and presented studies are retrospective and, for this reason, should serve to generate hypotheses for further prospective investigations rather than to guide our future clinical decisions. Moreover, in the last few years, there have been tremendous technological advances in AF catheter ablation (i.e., contact force, high power, short duration ablation, and pulsed-field ablation), including technologies that are still evolving in their daily clinical application, such as conduction system pacing, and that will hopefully improve the safety and efficacy of percutaneous treatment of AF, and eventual cardiac stimulation after AVNA [26,27]. These advancements have primarily not been included in the presented studies, and future investigations led by multidisciplinary teams should evaluate, possibly in a prospective randomized fashion, the clinical and economic impact of alternative approaches for selected AF patients unresponsive to the most modern percutaneous and pharmacological management.…”